Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal

Background: The molecular testing of KRAS mutation status in metastatic colorectal cancer patients is mandatory to identify patients eligible for anti-epidermal growth factor receptor monoclonal antibody therapy. Aim: To report the frequency of KRAS gene mutations in Chilean patients with colorectal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hurtado,Claudia, Encina,Gonzalo, Wielandt,Ana María, Zárate,Alejandro José, Castro,Magdalena, Carrillo,Katya, Kronberg,Udo, López-Köstner,Francisco
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2014
Materias:	KRAS protein, human Colorectal neoplasms Proto-oncogene proteins Receptor, epidermal growth factor
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014001100007
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872014001100007
record_format	dspace
spelling	oai:scielo:S0034-988720140011000072015-02-18Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectalHurtado,ClaudiaEncina,GonzaloWielandt,Ana MaríaZárate,Alejandro JoséCastro,MagdalenaCarrillo,KatyaKronberg,UdoLópez-Köstner,Francisco KRAS protein, human Colorectal neoplasms Proto-oncogene proteins Receptor, epidermal growth factor Background: The molecular testing of KRAS mutation status in metastatic colorectal cancer patients is mandatory to identify patients eligible for anti-epidermal growth factor receptor monoclonal antibody therapy. Aim: To report the frequency of KRAS gene mutations in Chilean patients with colorectal cancer (CRC). Material and Methods: A cohort of 262 Chilean patients with CRC aged 26 to 90 years (53% males), was studied. KRAS mutation status was analyzed by real-time polymerase chain reaction and correlated with clinicopathological data. Results: Ninety-eight patients (37%) were positive for KRAS mutations. G12D was the most common mutation with a frequency of 36.7%, followed by G12V (25.5%), G13D (17.3%), G12A (7.1%), G12C (6.1%), G12S (5.1%) and G12R (2%). The frequency of the mutation in left, right colon and rectal tumors was 37.8, 32.6 and 44.9%, respectively. Among tumors with mutations, 86.7% were well or moderately differentiated tumors and the rest were poorly differentiated. No significant associations between KRAS gene mutations and other clinicopathological features of the tumor were observed. Conclusions: The frequencies of KRAS mutations reported in this study are similar to frequencies reported for European and North-American populations, lower than in a Spanish study and higher than in a Peruvian study.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.142 n.11 20142014-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014001100007es10.4067/S0034-98872014001100007
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	KRAS protein, human Colorectal neoplasms Proto-oncogene proteins Receptor, epidermal growth factor
spellingShingle	KRAS protein, human Colorectal neoplasms Proto-oncogene proteins Receptor, epidermal growth factor Hurtado,Claudia Encina,Gonzalo Wielandt,Ana María Zárate,Alejandro José Castro,Magdalena Carrillo,Katya Kronberg,Udo López-Köstner,Francisco Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal
description	Background: The molecular testing of KRAS mutation status in metastatic colorectal cancer patients is mandatory to identify patients eligible for anti-epidermal growth factor receptor monoclonal antibody therapy. Aim: To report the frequency of KRAS gene mutations in Chilean patients with colorectal cancer (CRC). Material and Methods: A cohort of 262 Chilean patients with CRC aged 26 to 90 years (53% males), was studied. KRAS mutation status was analyzed by real-time polymerase chain reaction and correlated with clinicopathological data. Results: Ninety-eight patients (37%) were positive for KRAS mutations. G12D was the most common mutation with a frequency of 36.7%, followed by G12V (25.5%), G13D (17.3%), G12A (7.1%), G12C (6.1%), G12S (5.1%) and G12R (2%). The frequency of the mutation in left, right colon and rectal tumors was 37.8, 32.6 and 44.9%, respectively. Among tumors with mutations, 86.7% were well or moderately differentiated tumors and the rest were poorly differentiated. No significant associations between KRAS gene mutations and other clinicopathological features of the tumor were observed. Conclusions: The frequencies of KRAS mutations reported in this study are similar to frequencies reported for European and North-American populations, lower than in a Spanish study and higher than in a Peruvian study.
author	Hurtado,Claudia Encina,Gonzalo Wielandt,Ana María Zárate,Alejandro José Castro,Magdalena Carrillo,Katya Kronberg,Udo López-Köstner,Francisco
author_facet	Hurtado,Claudia Encina,Gonzalo Wielandt,Ana María Zárate,Alejandro José Castro,Magdalena Carrillo,Katya Kronberg,Udo López-Köstner,Francisco
author_sort	Hurtado,Claudia
title	Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal
title_short	Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal
title_full	Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal
title_fullStr	Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal
title_full_unstemmed	Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal
title_sort	prevalencia y características de mutaciones somáticas del gen kras en pacientes chilenos con cáncer colorrectal
publisher	Sociedad Médica de Santiago
publishDate	2014
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014001100007
work_keys_str_mv	AT hurtadoclaudia prevalenciaycaracteristicasdemutacionessomaticasdelgenkrasenpacienteschilenosconcancercolorrectal AT encinagonzalo prevalenciaycaracteristicasdemutacionessomaticasdelgenkrasenpacienteschilenosconcancercolorrectal AT wielandtanamaria prevalenciaycaracteristicasdemutacionessomaticasdelgenkrasenpacienteschilenosconcancercolorrectal AT zaratealejandrojose prevalenciaycaracteristicasdemutacionessomaticasdelgenkrasenpacienteschilenosconcancercolorrectal AT castromagdalena prevalenciaycaracteristicasdemutacionessomaticasdelgenkrasenpacienteschilenosconcancercolorrectal AT carrillokatya prevalenciaycaracteristicasdemutacionessomaticasdelgenkrasenpacienteschilenosconcancercolorrectal AT kronbergudo prevalenciaycaracteristicasdemutacionessomaticasdelgenkrasenpacienteschilenosconcancercolorrectal AT lopezkostnerfrancisco prevalenciaycaracteristicasdemutacionessomaticasdelgenkrasenpacienteschilenosconcancercolorrectal
_version_	1718436787797360640

Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal

Ejemplares similares